EAN 2024

Switching to fremanezumab from another type of calcitonin gene-related peptide pathway agent achieves a significant reduction in monthly migraine days.

The anti-CD40L monoclonal antibody frexalimab shows sustained benefit over 48 weeks in patients with relapsing multiple sclerosis.

Researchers have developed the anti-NMDAR Encephalitis One-Year Functional Status 2 score for predicting short- and long-term outcomes at the point of diagnosis.

Clinical characteristics of anti-AMPAR encephalitis in children include prodromal symptoms, movement disorders, and cerebellar symptoms.

Regular exercise and a ketogenic diet are effective in treating daytime sleepiness in patients with narcolepsy. 

High cumulative opioid use may increase the risk of dementia before the age of 90 years.

Degree of change in disease burden between symptom onset and initial clinical evaluation could better predict prognosis in amyotrophic lateral sclerosis.

Brain biopsy may be a safe and viable diagnostic procedure for unexplained neurological disorders of the CNS.

Changes to European healthcare systems will be needed if monoclonal antibodies are approved for the treatment of Alzheimer's disease.

An analysis of real-world data has found ocrelizumab to be an effective long-term treatment for relapsing multiple sclerosis.

Compensated hypogonadism in men with cluster headache indicates the androgen system plays a pathophysiological role.

People with epilepsy may have difficulty finding and retaining a job, with several factors impacting employment.

Patient ethnicity may affect access to reperfusion therapy for cerebral infarction in European countries.  

Tilted sleeping may help to reduce nocturnal hypertension in some patients with Parkinson's disease or parkinsonism.